Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
Keros Therapeutics (Nasdaq: KROS) has announced the presentation of three abstracts from its hematology program at the 66th American Society of Hematology (ASH) Annual Meeting from December 7-10, 2024. The presentations will showcase additional results from two ongoing Phase 2 clinical trials of elritercept (KER-050).
The trials focus on patients with lower-risk myelodysplastic syndrome (MDS) and myelofibrosis (MF). The presentations will highlight improvements in hematological parameters, quality of life, and clinical benefits of elritercept both as monotherapy and in combination with ruxolitinib. The abstracts were made public on the ASH website on November 5, 2024.
Keros Therapeutics (Nasdaq: KROS) ha annunciato la presentazione di tre abstract del suo programma di ematologia durante il 66° Congresso Annuale della Società Americana di Ematologia (ASH) che si svolgerà dal 7 al 10 dicembre 2024. Le presentazioni mostreranno risultati aggiuntivi di due trial clinici di Fase 2 in corso riguardanti elritercept (KER-050).
I trial si concentrano su pazienti con sindrome mielodisplastica (MDS) a rischio ridotto e mielofibrosi (MF). Le presentazioni evidenzieranno i miglioramenti nei parametri ematologici, nella qualità della vita e nei benefici clinici di elritercept sia come monoterapia che in combinazione con ruxolitinib. Gli abstract sono stati resi pubblici sul sito web dell'ASH il 5 novembre 2024.
Keros Therapeutics (Nasdaq: KROS) ha anunciado la presentación de tres resúmenes de su programa de hematología en el 66.º Congreso Anual de la Sociedad Americana de Hematología (ASH) que se llevará a cabo del 7 al 10 de diciembre de 2024. Las presentaciones mostrarán resultados adicionales de dos ensayos clínicos de Fase 2 en curso de elritercept (KER-050).
Los ensayos se centran en pacientes con síndrome mielodisplásico (MDS) de bajo riesgo y mielofibrosis (MF). Las presentaciones destacarán las mejoras en los parámetros hematológicos, la calidad de vida y los beneficios clínicos de elritercept tanto como monoterapia como en combinación con ruxolitinib. Los resúmenes se hicieron públicos en el sitio web de ASH el 5 de noviembre de 2024.
케로스 테라퓨틱스 (Nasdaq: KROS)는 제66회 미국 혈액학회 (ASH) 연례 회의에서 2024년 12월 7일부터 10일까지 자사의 혈액학 프로그램에 대한 3개의 초록을 발표한다고 발표했습니다. 이 발표는 엘리리텔셉트 (KER-050)에 대한 진행 중인 2상 임상 시험의 추가 결과를 보여줄 것입니다.
이 임상 시험은 저위험 골수형성이상증후군 (MDS) 및 골수섬유증 (MF) 환자에 초점을 맞추고 있습니다. 발표는 엘리리텔셉트의 단독 요법 및 룍소리티닙과의 병용 요법에서의 혈액학적 매개변수, 삶의 질 및 임상적 이점의 개선 사항을 강조합니다. 초록은 2024년 11월 5일 ASH 웹사이트에 공개되었습니다.
Keros Therapeutics (Nasdaq: KROS) a annoncé la présentation de trois résumés dans le cadre de son programme d'hématologie lors du 66ème Congrès Annuel de la Société Américaine d'Hématologie (ASH), qui se tiendra du 7 au 10 décembre 2024. Les présentations mettront en avant des résultats supplémentaires de deux essais cliniques de Phase 2 en cours concernant elritercept (KER-050).
Les essais se concentrent sur des patients présentant un syndrome myélodysplasique (MDS) de faible risque et une myélofibrose (MF). Les présentations mettront en avant les améliorations des paramètres hématologiques, de la qualité de vie et des bénéfices cliniques de l'elritercept, tant en monothérapie qu'en combinaison avec le ruxolitinib. Les résumés ont été rendus publics sur le site web de l'ASH le 5 novembre 2024.
Keros Therapeutics (Nasdaq: KROS) hat die Präsentation von drei Abstracts aus seinem Hämatologieprogramm beim 66. Jahreskongress der Amerikanischen Gesellschaft für Hämatologie (ASH) vom 7. bis 10. Dezember 2024 angekündigt. Die Präsentationen werden zusätzliche Ergebnisse aus zwei laufenden Phase-2-Studien zu elritercept (KER-050) präsentieren.
Die Studien richten sich an Patienten mit niedrigem Risiko für myelodysplastisches Syndrom (MDS) und Myelofibrose (MF). Die Präsentationen werden Verbesserungen der hämatologischen Parameter, der Lebensqualität und der klinischen Nutzen von elritercept sowohl als Monotherapie als auch in Kombination mit Ruxolitinib hervorheben. Die Abstracts wurden am 5. November 2024 auf der ASH-Website veröffentlicht.
- None.
- None.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology (“ASH”) Annual Meeting and Exposition to be held in person and virtually from December 7 through 10, 2024. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome (“MDS”) and one in patients with myelofibrosis (“MF”).
The following abstracts were posted to the ASH website on November 5, 2024, 9:00 a.m. Eastern time.
“Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)”
- Publication Number: 1825
- Session Name: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I
- Date: Saturday, December 7, 2024
- Presentation Time: 5:30 p.m. – 7:30 p.m. Pacific time
“Hematological Improvement and Other Clinical Benefits of Elritercept as Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 RESTORE Trial”
- Publication Number: 997
- Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis
- Date: Monday, December 9, 2024
- Presentation Time: 4:30 p.m. – 6:00 p.m. Pacific time
“Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial”
- Publication Number: 4591
- Session Name: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
- Date: Monday, December 9, 2024
- Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time
About Elritercept
Keros’ lead product candidate, elritercept, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-ß receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. Elritercept is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with MF.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, elritercept, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with MF. Keros’ second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ presentation plans for the upcoming ASH Annual Meeting and Exposition. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, elritercept, cibotercept and KER-065; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
What will Keros Therapeutics (KROS) present at the 2024 ASH Annual Meeting?
What are the key findings of elritercept (KER-050) in the Phase 2 trials by KROS?
When will KROS present their Phase 2 trial results for elritercept at ASH 2024?
